Impact BioMedical, INC. Deferred Federal Income Tax Expense (Benefit)
Impact BioMedical, INC. (IBO) reported Deferred Federal Income Tax Expense (Benefit) of -$2.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-11.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-03-11
- Impact BioMedical, INC. deferred federal income tax expense (benefit) for fiscal 2025 was -$2.00M, a 6760.00% decline from fiscal 2024.
- Impact BioMedical, INC. deferred federal income tax expense (benefit) for fiscal 2024 was $30.00K.
- Impact BioMedical, INC. deferred federal income tax expense (benefit) for fiscal 2023 was -$920.00K.
- Impact BioMedical, INC. deferred federal income tax expense (benefit) for fiscal 2022 was -$1.62M.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | -$2.00M 10-K · filed 2026-03-11 |
| 2024-12-31 | $30.00K 10-K · filed 2026-03-11 |
| 2023-12-31 | -$920.00K 10-K · filed 2025-03-28 |
| 2022-12-31 | -$1.62M 10-K · filed 2024-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |